Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
Authors
Keywords
-
Journal
Current Oncology Reports
Volume 22, Issue 4, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-03-21
DOI
10.1007/s11912-020-0897-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune checkpoint inhibitor-induced colitis: A comprehensive review
- (2019) Aniruddh Som et al. World Journal of Clinical Cases
- Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma
- (2019) Henry T. Quach et al. JAMA Oncology
- Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
- (2019) Jeroen M.k. de Filette et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Treatment Outcomes of Immune-Related Cutaneous Adverse Events
- (2019) Gregory S. Phillips et al. JOURNAL OF CLINICAL ONCOLOGY
- Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
- (2019) Joe-Elie Salem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control
- (2019) Michael S. Hughes et al. Cancer Medicine
- Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis
- (2019) Alexander Faje et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma
- (2018) Alexander T. Faje et al. CANCER
- Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
- (2018) Yinghong Wang et al. INFLAMMATORY BOWEL DISEASES
- A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors
- (2018) Adriana T. Lopez et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
- (2018) Syed S. Mahmood et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
- (2018) Kerry Reynolds et al. ONCOLOGIST
- Characterization of immune related hepatitis (irH) from immune checkpoint inhibitors (ICIs).
- (2018) Justine Vanessa Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors
- (2018) Alvaro Moreira et al. EUROPEAN JOURNAL OF CANCER
- Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
- (2018) Joe-Elie Salem et al. LANCET ONCOLOGY
- Diagnosis and Management of Immune Checkpoint Inhibitor‐Associated Neurologic Toxicity: Illustrative Case and Review of the Literature
- (2018) Kerry L. Reynolds et al. ONCOLOGIST
- Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy
- (2018) Karthik Suresh et al. Journal of Thoracic Oncology
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
- (2017) Jarushka Naidoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
- (2017) Hyunju Lee et al. Cancer Immunology Research
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- Thyroid dysfunctions secondary to cancer immunotherapy
- (2017) P. Chalan et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
- (2017) Michael Dougan Frontiers in Immunology
- Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
- (2017) James Luke Godwin et al. Journal for ImmunoTherapy of Cancer
- Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma
- (2016) Mary E. Roth et al. AMERICAN JOURNAL OF THERAPEUTICS
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Endocrinological side-effects of immune checkpoint inhibitors
- (2016) Francesco Torino et al. CURRENT OPINION IN ONCOLOGY
- Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies
- (2016) Vincent Sibaud et al. CURRENT OPINION IN ONCOLOGY
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
- (2016) V.R. Belum et al. EUROPEAN JOURNAL OF CANCER
- Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
- (2016) Jonathan L. Curry et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
- (2016) Camille Hua et al. JAMA Dermatology
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
- (2015) Mahnaz Mellati et al. DIABETES CARE
- Bolaamphiphiles as carriers for siRNA delivery: From chemical syntheses to practical applications
- (2015) Kshitij Gupta et al. JOURNAL OF CONTROLLED RELEASE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started